Protagonist Therapeutics (PTGX) EBIAT: 2017-2025
Historic EBIAT for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to -$39.3 million.
- Protagonist Therapeutics' EBIAT fell 18.46% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 73.13%. This contributed to the annual value of $275.2 million for FY2024, which is 448.54% up from last year.
- Protagonist Therapeutics' EBIAT amounted to -$39.3 million in Q3 2025, which was down 13.14% from -$34.8 million recorded in Q2 2025.
- Protagonist Therapeutics' 5-year EBIAT high stood at $207.3 million for Q1 2024, and its period low was -$41.0 million during Q2 2022.
- In the last 3 years, Protagonist Therapeutics' EBIAT had a median value of -$33.2 million in 2024 and averaged $10.0 million.
- In the last 5 years, Protagonist Therapeutics' EBIAT plummeted by 335.45% in 2021 and then soared by 714.80% in 2024.
- Over the past 5 years, Protagonist Therapeutics' EBIAT (Quarterly) stood at -$36.9 million in 2021, then rose by 7.35% to -$34.2 million in 2022, then soared by 179.94% to $27.3 million in 2023, then soared by 381.70% to $131.7 million in 2024, then declined by 18.46% to -$39.3 million in 2025.
- Its EBIAT stands at -$39.3 million for Q3 2025, versus -$34.8 million for Q2 2025 and -$11.7 million for Q1 2025.